Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06122506
Other study ID # 06190
Secondary ID NNF21OC0071037
Status Recruiting
Phase N/A
First received
Last updated
Start date November 9, 2023
Est. completion date March 2028

Study information

Verified date May 2023
Source University of Aarhus
Contact Lea K Hansen, MD
Phone +45 51910993
Email lea.hansen@clin.au.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Every year 15 million babies are born prematurely, which can lead to death or life-long disabilities. It is often caused by a dysfunction of the uterine cervix, which constitutes the narrow channel between the vagina and womb. During pregnancy, this channel must remain closed until the beginning of term labor. A weak cervix may not withstand the weight of the fetus, the amniotic fluid and the placenta and the cervical canal will open and cause late miscarriage or preterm delivery. To prevent this, a band (cerclage) can be applied around the cervix either vaginally or laparoscopically prior to a new pregnancy. To evaluate which treatment is best for most women, we will randomize (allocate by chance) women at risk for preterm birth, to either vaginal cerclage or laparoscopic cerclage in the Nordic countries and England


Description:

Both vaginal and abdominal cerclages are procedures that have been used to prevent preterm birth for more than 50 years. However, only one previous study (MAVRIC, Shennan et al. 2020) has compared the two methods in a randomised trial. Other than evidence from the MAVRIC trial there is uncertainty whether an abdominal cerclage should be preferred over vaginal cerclage, and which women would benefit from it the most. NORACT is an open, multicenter, superiority, randomized controlled trial with the overall objective to compare laparoscopic versus vaginal cerclage in woman in whom the clinician has equipoise as to whether an elective vaginal or abdominal cerclage will be the best intervention to prevent preterm birth. Participants will be recruited pre-pregnancy or in early pregnancy and randomised to vaginal or laparoscopic cerclage. If randomised to laparoscopic cerclage this will be inserted pre-pregnancy or before 10+0 weeks of gestation. The vaginal cerclage will be inserted during pregnancy, before 16+0 weeks of gestation. A total sample of 188 participants will be included to detect a target difference of 15% in the primary outcome between the two groups. The two primary outcomes are delivery before 32+0 weeks of gestation and baby death. The study extends from sites in Denmark, Sweden, Norway, Finland, Iceland, and the United Kingdom.


Recruitment information / eligibility

Status Recruiting
Enrollment 188
Est. completion date March 2028
Est. primary completion date December 2027
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women in whom the clinician has equipoise as to whether an elective vaginal or abdominal cerclage will be the best intervention to prevent preterm birth. - Not yet pregnant or <10 weeks' pregnant. Exclusion Criteria: - Any circumstance under which the clinician is not willing to randomize is an exclusion criterion. - Any condition or circumstance under which laparoscopic or vaginal cerclage surgery is contraindicated (i.e. on-going pregnancy of more than 10+0 gestational weeks). - Language difficulties.

Study Design


Intervention

Procedure:
Laparoscopic cerclage
Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.
Vaginal cerclage
Transvaginal cerclage in pregnant women.

Locations

Country Name City State
Denmark Aarhus University Hospital Aarhus N
Denmark Rigshospitalet København

Sponsors (6)

Lead Sponsor Collaborator
Aarhus University Hospital Hvidovre University Hospital, Odense University Hospital, Oslo University Hospital, Rigshospitalet, Denmark, Viborg Regional Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Delivery <32+0 weeks of gestation. In the first subsequent viable pregnancy beyond 14+0 weeks of gestation. First prioritized primary outcome. At birth.
Primary Baby death. Loss of a viable pregnancy beyond 14+0 weeks of gestation, miscarriage, stillbirth or death of a live born infant. Second prioritized primary outcome. From birth - four weeks after due date. In the first subsequent viable pregnancy beyond 14 weeks of gestation.
Secondary Maternal mortality - surgery related. Death. 30 days after insertion of laparoscopic or vaginal cerclage.
Secondary Maternal mortality. Death. From time of randomisation - 42 days after delivery.
Secondary Maternal morbidity - surgery related. Admission to ICU or a unit that provides 24-h medical supervision and is able to provide mechanical ventilation or continuous vasoactive drug support. 30 days after insertion of laparoscopic or vaginal cerclage.
Secondary Maternal morbidity Admission to ICU or a unit that provides 24-h medical supervision and is able to provide mechanical ventilation or continuous vasoactive drug support. From time of randomisation - 42 days after delivery.
Secondary Harm to participant - surgery related. One or more of the following: Damage to internal organs, need for re-operation, thromboembolic events (defined as deep vein thrombosis, pulmonary embolism or stroke), maternal cardiopulmonary arrest. 30 days after insertion of laparoscopic or vaginal cerclage.
Secondary Harm to participant One or more of the following: Damage to internal organs, thromboembolic events (defined as deep vein thrombosis, pulmonary embolism or stroke), maternal cardiopulmonary arrest. From time of cerclage procedure - 42 days after delivery.
Secondary Bleeding - surgery related. Blood loss > 500 ml. 30 days after insertion of laparoscopic or vaginal cerclage.
Secondary Bleeding - pregnancy related. Blood loss > 1000 ml. From time of cerclage procedure - 42 days after delivery.
Secondary Maternal infection - surgery related. Leading to antibiotic treatment, but not ICU. 30 days after insertion of laparoscopic or vaginal cerclage.
Secondary Maternal infection - pregnancy related. Leading to antibiotic treatment, but not ICU From time of cerclage procedure - 42 days after delivery
Secondary Maternal serious infection - pregnancy related. Admission to ICU due to serious infection. From time of cerclage procedure - 42 days after delivery.
Secondary Maternal serious infection - surgery related. Admission to ICU due to serious infection. 30 days after insertion of laparoscopic or vaginal cerclage.
Secondary PPROM. Preterm prelabour rupture of membranes, in the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Threatened preterm labour. Threatened preterm labour requiring admission and intervention, in the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Onset of labour. Spontaneous labor contractions, PROM, induction of labor, c-section. In the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Mode of birth. Unassisted vaginal, assisted vaginal (ventouse or forceps), caesarean section (planned, non-planned). In the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Modified neonatal mortality. Death of a liveborn child > 22+0 weeks of gestation. From birth - four weeks after due date. In the first subsequent viable pregnancy beyond 14 weeks of gestation.
Secondary Neonatal mortality. Death in the 1st 28 days of life > 22+0 weeks of gestation. From birth - 28 days post delivery. In the first subsequent viable pregnancy beyond 14 weeks of gestation.
Secondary Fetal loss. Composite of late miscarriage and stillbirth, in the first subsequent viable pregnancy beyond 14 weeks of gestation. At due date.
Secondary Late miscarriage. Loss of viable pregnancy between gestational age 14+0-21+6, in the first subsequent viable pregnancy beyond 14 weeks of gestation. At due date.
Secondary Gestational age at birth. Gestational age at birth, weeks and days, in the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Delivery < 28 weeks. Birth before gestational age 28+0, in the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Delivery < 34 weeks. Birth before gestational age 34+0, in the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Delivery < 37 weeks. Birth before gestational age 37+0, in the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Birthweight. Grams. In the first subsequent viable pregnancy beyond 14 weeks of gestation. At birth.
Secondary Neonatal admission. Number of consecutive days in hospital within 28 days from time of delivery. In the first subsequent viable pregnancy beyond 14 weeks of gestation.
Any admission counts (SCBU, maternity ward, NICU)
From birth - four weeks after due date.
Secondary CNS morbidity. Intraventricular Hemorrhage Grade III and IV and/or Periventricular leukomalacia. In the first subsequent viable pregnancy beyond 14 weeks of gestation. From birth - four weeks after due date.
Secondary Ocular morbidity. Retinopathy requiring treatment. In the first subsequent viable pregnancy beyond 14 weeks of gestation. From birth - four weeks after due date.
Secondary Gastrointestinal morbidity. Necrotizing Enterocolitis (NEC) and/or SIP (Spontaneous intestinal perforation), requiring surgery. In the first subsequent viable pregnancy beyond 14 weeks of gestation. From birth - four weeks after due date.
Secondary Respiratory support. Mechanical ventilation or non-invasive ventilation. In the first subsequent viable pregnancy beyond 14 weeks of gestation. From birth - four weeks after due date.
Secondary Respiratory distress syndrome (RDS). Need for surfactant treatment. In the first subsequent viable pregnancy beyond 14 weeks of gestation. First two days of life.
Secondary Early onset neonatal infection. >5 days of i.v. antibiotics, where the treatment commences within the first week of life. In the first subsequent viable pregnancy beyond 14 weeks of gestation. From birth - four weeks after due date.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Not yet recruiting NCT03418311 - Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome N/A
Not yet recruiting NCT03418012 - Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB N/A
Completed NCT02993744 - Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone N/A
Active, not recruiting NCT02673216 - Infection and Adverse Pregnancy Outcome
Completed NCT01683565 - Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Phase 4
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Completed NCT01412931 - Protein and Ultrasound Indicators of Preterm Birth N/A
Completed NCT02606058 - The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures? N/A
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Completed NCT00422526 - Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial Phase 3
Enrolling by invitation NCT04251260 - Effectiveness of Positioning in Preterm Neonates N/A
Completed NCT03668860 - India Dexamethasone and Betamethasone Phase 1
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Completed NCT02225353 - Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery Phase 2
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT03144141 - Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery N/A
Completed NCT05210985 - Examination of the Relationship Between Home Affordances With Development
Completed NCT04811742 - Effect of Immersion Bathing and Showering Applications on Comfort Level and Physiological Parameters of Newborn N/A

External Links